First Sanaria of the malaria vaccine trial yields positive results
Main category: tropical diseases
Also included in: immune system / vaccines
Article date: 09 Sep 2011-2: 00 PDT window.fbAsyncInit = function() {FB.init({_appId:_'aa16a4bf93f23f07eb33109d5f1134d3',_status:_true,_cookie:_true,_xfbml:_true,_channelUrl:_'http://www.medicalnewstoday.com/scripts/facebooklike.html'});}; (function() {var s = document.createElement('script'); = true e.async; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e);}());
email to a friend 
printer friendly 
opinions
Positive results from the initial phase 1 clinical trial in 80 healthy volunteers and complementary pre-clinical studies of the Sanaria ® PfSPZ vaccine are published in the online issue of science.
"This is the first indication that a highly effective malaria vaccine may be available that can be used to eliminate Plasmodium falciparum malaria in geographically defined areas and prevent malaria in travelers," says Fred Binka, MD, PhD, Dean of the school of public health, University of Ghana.
Medical science has long been on a quest vaccine for on effective malaria. There are some 250 million malaria cases worldwide annually, with as many as 800,000 deaths, most of them children in Africa.
An effective vaccine that prevents malaria infection is considered the only tool that intends to eventually conquer this disease. Such a vaccine must prevent infection in greater than 80% of recipients for 6-24 months in order to be suitable for elimination campaigns and protecting travelers.
High level protection has only been achieved in humans who were immunized by the bite of mosquitoes that inoculated live, sporozoite stage Plasmodium falciparum parasites of that had been weakened by irradiation or drugs. Immune cells called cytotoxic or killer CD8 + T cells that are activated by the sporozoites are responsible for the protection against malaria after immunization with irradiated sporozoites.
It is not feasible to immunize large numbers of humans by bite of mosquitoes carrying sporozoites, and it was considered impossible to manufacture a sporozoite vaccine that met regulatory standards.
"Therefore, despite the high level protection induced by sporozoites administered by mosquito bite, before the breakthroughs reported in the Science paper, no human had ever been immunized with a sporozoite vaccine administered by needle and syringe," says Stephen L. Hoffman, MD, Sanaria's Chief Executive and scientific officer.
Sanaria has developed a unique manufacturing process that meets FDA standards to produce the Sanaria ® PfSPZ vaccine. The vaccine is composed of attenuated (weakened) malaria sporozoites that are the stage transmitted to humans by mosquitoes.
The vaccine which tested by a team of biomedical scientists from the U.S. military malaria vaccine program (Naval Medical Research Center and Walter Reed Army Institute of research); University of Maryland Center for vaccine development; Vaccine research center, National Institute of Allergy and infectious diseases, national institutes of health; Sanaria Inc.; PATH malaria vaccine initiative; and protein potential, LLC. The principal findings and conclusions reported in science are:
-Sanaria ® PfSPZ vaccine what safe and well tolerated in this phase 1 clinical trial in humans.
-Sanaria ® PfSPZ vaccine administered in the skin by needle and syringe to humans was found immunogenic and protective, but not nearly to the levels after mosquito bite immunization.
-Sanaria ® PfSPZ vaccine administered by intravenous injection to animals, triggered unprecedented high levels of malaria parasite-specific CD8 + T cells in the liver, the hallmark of protective immunity.
-Sanaria ® PfSPZ vaccine is highly potent.
Based on these results, the PfSPZ vaccine administered by intravenous injection will soon be assessed in a clinical trial at the vaccine research center, NIAID, NIH in the United States. A trial in Tanzania is also being planned.
Professor Marcel Tanner, Director Swiss tropical and public health Institute, comments, "Sanaria has ushered in a whole new era of malaria vaccine development and testing." "We are heartened that a path toward a vaccine that can be used to entirely prevent infection with Plasmodium falciparum malaria has been established and will be rigorously pursued."
Internationally renowned malariologist and vaccinologist Professor Michael good of Griffith University, Australia says, "the results presented in science represent an enormous step toward the development of the highly effective malaria preventative vaccine generally recognized as essential for the elimination and eventually the eradication of the scourge malaria."
Source: Sanaria Inc
Article adapted by medical news today from original press release.Visit our tropical diseases section for the latest news on this subject.
There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:APA
Sanaria Inc (2011, September 9). Initial trial of Sanaria\'s malaria vaccine yields positive results. Medical news today. Retrieved September 9, 2011 from http://www.medicalnewstoday.com/releases/234137.php MLA
Sanaria Inc. "initial trial of Sanaria\'s malaria vaccine yields positive results". Medical news today, September 9, 2011. Web. 9 Sep, 2011.
Please note: If no author information is provided, the source is cited instead.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact our news editor
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send press any medical news or health news releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
View the original article here
0 komentar:
Posting Komentar